Previous results in non-HIV/AIDS populations have demonstrated that DLBCL patients with active mTOR pathway have a trend toward shorter OS when compared to patients with mTOR negative tumors [11]. This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.